Finerenone

Summary

Finerenone (CHEMBL2181927) is an approved small molecule (ATC C03DA05) targeting NR3C2; indicated across 6 conditions including chronic kidney disease and cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03DA05
• Targets: 1 (NR3C2)
• Indications: 6 conditions
• Clinical trials: 54

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2181927
Name	Finerenone
Type	Small molecule
Max phase	4
ATC	C03DA05

Also known as: Finerenona, Finerenone, Kerendia, FINERENONE

Patent coverage: 358 distinct patent families (750 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 672 (90%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NR3C2	Mineralocorticoid receptor	Antagonist	7.74	0%	P08235

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Mineralocorticoid receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C2	7.8	IC50	16	nM	CHEMBL_ACT_12163939
NR3C2	7.75	IC50	18	nM	CHEMBL_ACT_12623071
NR3C2	7.75	IC50	18	nM	CHEMBL_ACT_18033284
NR3C2	7.24	IC50	58	nM	CHEMBL_ACT_18033297

Target pathways

Aggregated over 1 target gene(s): NR3C2.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Cellular responses to stress	1	NR3C2
SUMOylation	1	NR3C2
SUMO E3 ligases SUMOylate target proteins	1	NR3C2
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	1	NR3C2
Nuclear Receptor transcription pathway	1	NR3C2
Metabolism of proteins	1	NR3C2
SUMOylation of intracellular receptors	1	NR3C2
Post-translational protein modification	1	NR3C2
Cellular responses to stimuli	1	NR3C2

Dominant GO biological processes

GO term	Targets
regulation of transcription by RNA polymerase II	1
signal transduction	1
nuclear receptor-mediated steroid hormone signaling pathway	1
positive regulation of non-canonical NF-kappaB signal transduction	1
regulation of DNA-templated transcription	1
cellular response to hormone stimulus	1
response to lipid	1

Indications & clinical

Indications

6 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	4	MONDO:0005300	EFO:0003884
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
type 2 diabetes mellitus	4	MONDO:0005148	MONDO:0005148
heart failure	3	MONDO:0005252	EFO:0003144
diabetic kidney disease	3	MONDO:0005016	EFO:0000401
diabetes mellitus	3	MONDO:0005015	EFO:0000400

Clinical trials

Total trials: 54.

Phase distribution

Phase	Trials
PHASE4	19
PHASE3	14
PHASE2	9
Not specified	8
PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05887817	PHASE4	ACTIVE_NOT_RECRUITING	Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
NCT06457074	PHASE4	RECRUITING	Finerenone for Patients With Primary Aldosteronism (FAIRY)
NCT06727409	PHASE4	RECRUITING	Use of Clinical-trials and Simulation Models to Estimate Cost-effectiveness of Non-steroidal Mineralocorticoid Antagonists, RASi and SGLT2i as Triple Therapy With Type 2 Diabetes and Chronic Kidney Disease
NCT06954090	PHASE4	ENROLLING_BY_INVITATION	Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
NCT07155694	PHASE4	NOT_YET_RECRUITING	Role of Finerenone in African American Veterans With Diabetic Kidney Disease
NCT07235891	PHASE4	NOT_YET_RECRUITING	Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease
NCT07239570	PHASE4	RECRUITING	A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
NCT07351864	PHASE4	NOT_YET_RECRUITING	Finerenone Plus SGLT2 Inhibitors in Heart Failure
NCT07397650	PHASE4	RECRUITING	Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure
NCT07442448	PHASE4	ENROLLING_BY_INVITATION	Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure
NCT07523867	PHASE4	NOT_YET_RECRUITING	Spironolactone Alternate Dosing vs Finerenone in Elevated Potassium - K Safety Study
NCT07537088	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
NCT07547878	PHASE4	NOT_YET_RECRUITING	Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)
NCT07583173	PHASE4	NOT_YET_RECRUITING	Effect of Finerenone on Myocardial Fibrosis and Cardiac Function in HFmrEF/HFpEF Patients
NCT05814770	PHASE4	UNKNOWN	Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism
NCT05924620	PHASE4	COMPLETED	Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism
NCT06094920	PHASE4	COMPLETED	Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
NCT06164379	PHASE4	UNKNOWN	Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism
NCT06381323	PHASE4	COMPLETED	The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism
NCT06008197	PHASE3	RECRUITING	A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06024746	PHASE3	RECRUITING	A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
NCT06033950	PHASE3	RECRUITING	A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
NCT06058585	PHASE3	RECRUITING	The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
NCT06082063	PHASE3	RECRUITING	Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
NCT06580288	PHASE3	NOT_YET_RECRUITING	Effect of Finerenone in IgA Nephropathy
NCT07223502	PHASE3	RECRUITING	A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
NCT07270367	PHASE3	NOT_YET_RECRUITING	Finerenone and Cardiac Remodeling
NCT07575672	PHASE3	NOT_YET_RECRUITING	Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT02540993	PHASE3	COMPLETED	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
NCT02545049	PHASE3	COMPLETED	Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
NCT04435626	PHASE3	COMPLETED	Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
NCT05047263	PHASE3	COMPLETED	A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
NCT05901831	PHASE3	COMPLETED	A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys’ Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT06059664	PHASE2	RECRUITING	The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
NCT07594145	PHASE2	NOT_YET_RECRUITING	Precision T1D Platform - New Therapies for Cardio-Renal Complications
NCT01345656	PHASE2	COMPLETED	BAY94-8862 Dose Finding Trial in Subjects With Chronic Heart Failure and Mild (Part A) or Moderate (Part B) Chronic Kidney Disease
NCT01807221	PHASE2	COMPLETED	Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
NCT01874431	PHASE2	COMPLETED	Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
NCT01955694	PHASE2	COMPLETED	Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
NCT01968668	PHASE2	COMPLETED	Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

25 molecules share ≥1 primary target. Top 25 by shared-target count:

Molecule	Source	Status	Shared targets
EPLERENONE	ChEMBL + PubChem	Phase 4 (approved)	NR3C2
BUDESONIDE	ChEMBL	Phase 4 (approved)	NR3C2
DEXAMETHASONE	ChEMBL	Phase 4 (approved)	NR3C2
FLUTICASONE FUROATE	ChEMBL	Phase 4 (approved)	NR3C2
FLUTICASONE PROPIONATE	ChEMBL	Phase 4 (approved)	NR3C2
HYDROCORTISONE	ChEMBL	Phase 4 (approved)	NR3C2
HYDROCORTISONE BUTYRATE	ChEMBL	Phase 4 (approved)	NR3C2
MEDROXYPROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C2
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	NR3C2
PREDNISOLONE	ChEMBL	Phase 4 (approved)	NR3C2
PROGESTERONE	ChEMBL	Phase 4 (approved)	NR3C2
SPIRONOLACTONE	ChEMBL	Phase 4 (approved)	NR3C2
ASOPRISNIL	ChEMBL	Phase 3	NR3C2
BALCINRENONE	ChEMBL	Phase 3	NR3C2
CORTICOSTERONE	ChEMBL	Phase 3	NR3C2
ALDOSTERONE	ChEMBL	Phase 2	NR3C2
LY2623091	ChEMBL	Phase 2	NR3C2
METRIBOLONE	ChEMBL	Phase 2	NR3C2
MT-3995	ChEMBL	Phase 2	NR3C2
ONAPRISTONE	ChEMBL	Phase 2	NR3C2
STANOLONE	ChEMBL	Phase 2	NR3C2
TUROFEXORATE ISOPROPYL	ChEMBL	Phase 2	NR3C2
Enzalutamide	PubChem	Approved	NR3C2
Fludrocortisone	PubChem	Approved	NR3C2
ursodiol	PubChem	Approved	NR3C2